Expertise in
22
conditions

Valeria A. Sansone

Milan, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
22
conditions
Milan, IT 

Overview

Valeria Sansone practices practicing medicine in Milan, Italy.

Ms. Sansone is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Paramyotonia Congenita, Myotonic Dystrophy, Myotonic Dystrophy Type 2, Gastrostomy, and Osteotomy.

She is actively involved in clinical research, co-authoring 237 peer reviewed articles and participating in 7 clinical trials.

Gender

Female

Locations

Milan, Italy
Other Locations
Rome, 00168, Italy
Novara, Italy
San Donato Di Ninea, Italy
Milanesi, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Enrollment Status: Recruiting
Publish Date: June 10, 2026
Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Enrollment Status: Completed
Publish Date: February 24, 2026
Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy
Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy
Enrollment Status: Completed
Publish Date: March 11, 2025
Intervention Type: Other
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
View 6 Less Clinical Trials

237 Total Publications

Exploring Treatment Expectations and Clinical Meaningfulness in Spinal Muscular Atrophy Using the Goal Attainment Scale.
Exploring Treatment Expectations and Clinical Meaningfulness in Spinal Muscular Atrophy Using the Goal Attainment Scale.
Journal: Archives of rehabilitation research and clinical translation
Published: June 22, 2026

Frequently Asked Questions about Valeria A. Sansone

Is Valeria A. Sansone a top-rated expert for Paramyotonia Congenita?

MediFind is an objective health platform that identifies experts based on real-world data. Valeria A. Sansone is classified as an Elite expert for Paramyotonia Congenita, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Valeria A. Sansone participate in research or clinical trials?

Yes. Valeria A. Sansone has published 237 articles and abstracts on conditions like Paramyotonia Congenita. You can view a list of Valeria A. Sansone's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sansone's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile